GLP1R and hyperlipidemia: Despite apparent favorable effects on some established cardiovascular risks factors, such as hyperglycemia and hyperlipidemia, the long-term role of this GLP-1 analogue in primary prevention of CVD in individuals with T2D remains controversial, due to limited available data and potential issues of current methods of CVD risk assessment.